Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
NCT02706353 · M.D. Anderson Cancer Center · PHASE1/PHASE2 · terminated · last registry update 2025-11-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “\<75% participant accrual” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD40 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-06-04Also stopped (suspended): James Cleary, MD, PhD, ZIMBERELIMAB + DOMVANALIMAB (NCT05419479)
- 2026-05-18Results posted on the registry: Novartis Pharmaceuticals, CFZ533 (NCT03905525)
- 2026-02-06Results posted on the registry: Novartis Pharmaceuticals, CFZ533 + Placebo to CFZ533 (NCT03827798)
- 2025-11-21Results posted on the registry: Hoffmann-La Roche, Nab-Paclitaxel + Gemcitabine (NCT03193190)
- 2025-06-29Results posted on the registry: Novartis Pharmaceuticals, Iscalimab (NCT04541589)
- 2025-05-16Also stopped (terminated): Novartis Pharmaceuticals, CFZ533 + Tacrolimus - MMF - corticosteroids (NCT03781414)
- 2025-01-17Results posted on the registry: Novartis Pharmaceuticals, CFZ533 (NCT04129528)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision